La Merie Publishing

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: A Landscape Analysis of Stakeholders, Technologies, Targets, Business and Financing From an Industry Perspective

R&D Drug Pipeline Database: 1-Year Subscription

Report Package - 4 for 2: "Drug the Undruggable" Technologies

Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: A Landscape Analysis of Companies, Technologies, Targets, Investors and Partners from an Industry Perspective

RNA-Targeted Small Molecules 2019: A Landscape Analysis of Companies, Technologies, Targets, Investors and Partners from an Industry Perspective

Competitor Analysis: Bispecific Antibodies for Immuno-Oncology & Other Diseases

2 Reports Bundle - Competitor Analysis: Bispecific Antibodies for Immuno-Oncology & Other Diseases plus T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: A Business, Stakeholder, Technology and Pipeline Analysis

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: A Business, Stakeholder, Technology and Pipeline Analysis

4 Reports Bundle: Immuno-Oncology - Inhibitory and Stimulatory Immunomodulators

6 Reports Bundle: Immunotherapeutics Targeting MAGE-A, NY-ESO-1, hTERT, WT1, PRAME and Survivin

2 Reports Bundle: TCR-Based Antibody and T-Cell Immunotherapy

TCR Engineered T-Cell Therapy 2018: An Industry Analysis of Technologies, Pipelines, Stakeholders & Deals

Intracellular Targets Made Druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: An Industry Analysis of Technologies, Stakeholders, Deals & Trends

Competitor Analysis: Anti-VEGF and Anti-VEGF-R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis - 2017 Update

2 Reports Bundle: Immunotherapy with Oncolytic Viruses and mRNA Vaccines & Therapeutics